enGenes Biotech – Showing end-to-end bioprocessing at BIO-Europe 2025

Vienna, Austria: – enGenes Biotech GmbH (enGenes) will show its highly advanced bioprocessing solutions in protein expression and vaccine development at Europe’s flagship life sciences partnering conference, BIO-Europe 2025, this year in Vienna.

The enGenes team will join other hi-tech biotech companies as part of a combined national presence at the Austrian Pavilion operated by LISAvienna, located at C32 GL in Hall C of the Messe Wien expo center.

Enhanced yield expression

The enGenes stand displays will showcase its unique proprietary high-yield expression and purification platforms, its end-to-end bioprocessing services and innovative products, including endonuclease and affinity ligands for faster vaccine development.

Business Development Manager Dr. Ophelia Gevaert will lead the enGenes presence on stand and at BIO-Europe’s many online and face-to-face networking opportunities.

High performance bioprocessing

“We are delighted that Bio-Europe with its excellent opportunities to strengthen ties with existing partners and explore new collaboration opportunities is this year being held in our home city of Vienna and that we will be able to join in representing the vibrant Austrian biotech community,” said Ophelia Gevaert.

“We look forward to many productive conversations about new ways to apply advanced  enGenes capabilities and technologies in high-performance bioprocessing, such as scalable recombinant production of difficult targets and vaccine antigens or antibiotic-free, growth-decoupled processes that boost yields. We also want to find partners for our new portfolio of capture tools and enzymes to streamline purification, offering high-performance affinity ligands—including protein A solutions—and introducing an endonuclease line to improve pDNA and protein workflows,” Dr. Gevaert added.

About enGenes Biotech

With more than a decade of proven expertise, enGenes Biotech develops bioprocesses that consistently outperform conventional approaches. The company’s proprietary technology platforms deliver higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli. These directly translate into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.

enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. It can deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position on the global marketplace.

The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.

Find out more at: https://www.engenes.cc

About BIO-Europe 2025

BIO-Europe® is a premier partnering conference that annually attracts an international galaxy of decision makers from the world’s biotech, pharma and investment communities for high caliber networking.

The three-day 2025 event opens November 3 at the Messe Wien Convention Center in Vienna, with a further two days of online networking scheduled for November 4-5.

Featuring a sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

The event is expected to involve close to 6,000 visitors representing more than 3,000 companies from more than 60 nations. With a conference agenda structured around the headline theme of European Biopharma Innovation, the program features Partnering and Investment Trends, Therapeutics Insights, and Ecosystem Innovation. The program also features more than 20 workshops and panels, with thousands of licensing opportunities posted.

The event is organized by Informa Connect with more information at: https://informaconnect.com/bioeurope/

Resources

Email Ophelia Gevaert to set up a meeting in Vienna.
Click on enGenes Biotech Tailored Solutions to learn more.